Liz Highleyman ✓

@LizHighleyman · San Francisco · joined 21 Mar 2009

Medical journalist. Science editor for @POZmagazine, Hep & CancerHealth. Words for @aidsmap, @Slate, @eBARnews. Research beagle adopter. Same handle on Blue.

16 337Followers

5 808Following

53 436Posts total

35.2KViews on collected posts

Son gönderiler

Liz Highleyman ✓@LizHighleyman10 Sep

Wow, someone in the investment world is saying this in Forbes. A drum I’m constantly beating: Medical innovation is important, but advances need to be accessible without devoting an ever-growing share of the economy to pharmaceuticals. https://t.co/3u7rhAHPVS 90 views · 2 likes · 1 reposts · 1 replies Open on X →

Liz Highleyman ✓@LizHighleyman9 Sep

I’ve been seeing more cancer drugs pulled lately for failing confirmatory trials, which is how accelerated approval is supposed to work. Interestingly, we didn’t really see this with HIV, which FDA & activists first devised AA for in the 1990s. As better drugs came along, old 237 views · 1 likes · 0 reposts · 0 replies Open on X →

Liz Highleyman ✓@LizHighleyman9 Sep

This is how I feel about animal testing. There’s some types of medical research that cannot yet be done with non-animal models. But breeding beagles for old-fashioned toxicology testing is obsolete. There’s a lot of low-hanging fruit before we get to the hardest cases 265 views · 0 likes · 0 reposts · 0 replies Open on X →

Liz Highleyman ✓@LizHighleyman9 Sep

The same can be said of semaglutide & tirzepatide. Clinical trials are often designed to determine a maximum effective & tolerated dose for the sickest patients. I’m thriving on 0.7 mg tirz. 410 views · 2 likes · 0 reposts · 1 replies Open on X →

Liz Highleyman ✓@LizHighleyman9 Sep

Agreed. The proposed “solution” seems to be putting the current frontier companies, allied with the Trump administration, in control of who can work on AI. 293 views · 0 likes · 0 reposts · 0 replies Open on X →

Liz Highleyman ✓@LizHighleyman9 Sep

1/ I was on the @FDAOncology ODAC for sotorasib, a KRAS G12Ci tested in NSCLC. We voted no, almost unanimously. A year later adagrasib + cetuximab got accelerated approval (AA) for colorectal cancer based on KRYSTAL-1. KRYSTAL-10 was a phase 3 RCT testing that combo and just 14.4K views · 69 likes · 13 reposts · 4 replies Open on X →

Liz Highleyman ✓@LizHighleyman9 Sep

If you are not obese, riddled with metabolic diseases, live a legitimately active lifestyle, and follow a strict clean diet, be cautious of making Reta dosage decisions based on trial data. 19.5K views · 94 likes · 4 reposts · 17 replies Open on X →

Aynı büyüklükteki hesaplara karşı

Son 90 güne ait 7 gönderi, 10K–100K takipçi aralığıyla yan yana. hem erişimde hem etkileşimde benzerlerinin altında.

Medyan görüntülenme293bu hesap92410K–100K için medyan

Erişim, %1.79%bu hesap3.62%10K–100K için medyan

Etkileşim, %0.59%bu hesap1.52%10K–100K için medyan

Ölçüt	Bu hesap	10K–100K için medyan	Oran
Gönderi başına medyan görüntülenme	293	924	0.32×
Erişim (görüntülenme ÷ takipçi)	1.79%	3.62%	0.50×
Etkileşim oranı	0.59%	1.52%	0.39×

Bu aralıktaki diğer hesaplar → Başka bir hesapla karşılaştır → Bu kıyas değerleri nasıl kuruluyor →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

19.5K9 Sep

14.4K

293

410

265

237

9010 Sep

Last 7 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.59%9 Sep

0.60%

0.00%

0.73%

0.00%

0.42%

4.44%10 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes80.4%168 in total

Reposts8.6%18 in total

Replies11.0%23 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Son gönderiler

Aynı büyüklükteki hesaplara karşı

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Benzer hesaplar